A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/01/2004	EP1481680A1 Use of S1P
12/01/2004	EP1481678A1 Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
12/01/2004	EP1481677A1 Cosmetic and/or dermatological composition containing ascorbic acid or its derivatives stabilised by at least one amphiphilic polymer chosen from oligomers or polymers derived from polyisobutylene
12/01/2004	EP1481676A1 Phytoestrogens and probiotic for women's health
12/01/2004	EP1481675A1 Body temperature elevating agents
12/01/2004	EP1481674A1 Process for recovering statin compounds from a fermentation broth
12/01/2004	EP1481673A1 Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
12/01/2004	EP1481672A1 Compositions for ameliorating fecal properties
12/01/2004	EP1481671A1 Compositions and foods for improving lipid metabolism
12/01/2004	EP1481670A1 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome
12/01/2004	EP1481669A1 Use of polyhydroxy phenols and polyphenols for modulating p-selectin activity
12/01/2004	EP1481668A1 Use of anti-glaucoma drugs to treat visual field defects associated with the use of a GABAergic agent
12/01/2004	EP1481667A1 NEP inhibitors for the treatment of female sexual dysfunction
12/01/2004	EP1481666A1 A composition for re-establishment of the vaginal ecosystem
12/01/2004	EP1481251A2 Estrogen receptor interaction with a transcription factor
12/01/2004	EP1481250A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
12/01/2004	EP1481093A2 MODULATION OF TYPE II&bgr; PHOSPHOINOSITIDE PHOSPHATE KINASE
12/01/2004	EP1481089A2 Methods based on hormone dependency of primary cancer cells
12/01/2004	EP1481077A2 Mitotic kinesin inhibitors
12/01/2004	EP1481063A1 Delta 6-desaturases from primulaceae, expressing plants and pufa-containing oils
12/01/2004	EP1481000A2 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
12/01/2004	EP1480999A2 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
12/01/2004	EP1480996A1 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
12/01/2004	EP1480995A2 Cks1 INHIBITORS
12/01/2004	EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof
12/01/2004	EP1480986A1 Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
12/01/2004	EP1480985A1 Salt of benzosulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations
12/01/2004	EP1480984A2 Condensed camptothecins as antitumor agents
12/01/2004	EP1480983A1 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
12/01/2004	EP1480982A2 Modified fluorinated nucleoside analogues
12/01/2004	EP1480981A1 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
12/01/2004	EP1480980A2 Syntheses of quinazolinones
12/01/2004	EP1480978A1 Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one
12/01/2004	EP1480977A2 Substituted aryl compounds for treatment of disease
12/01/2004	EP1480976A1 Thiazole derivatives as npy receptor antagonists
12/01/2004	EP1480975A2 Chemical compounds
12/01/2004	EP1480974A1 Heterocyclylmethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors
12/01/2004	EP1480973A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
12/01/2004	EP1480972A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
12/01/2004	EP1480971A1 Isoquinoline derivatives
12/01/2004	EP1480970A1 Quinoline derivatives
12/01/2004	EP1480966A1 Compounds and methods of treating cell proliferative diseases
12/01/2004	EP1480964A1 Inhibiteurs de l'angiogenese
12/01/2004	EP1480963A1 Method for producing 3-amidinophenylalanine derivatives
12/01/2004	EP1480962A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
12/01/2004	EP1480961A1 Glutaminyl based dpiv inhibitors
12/01/2004	EP1480960A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments
12/01/2004	EP1480959A1 Piperazine derivatives as anti-inflammatory agents
12/01/2004	EP1480958A1 Uracil-thioether
12/01/2004	EP1480957A1 Hppars activators
12/01/2004	EP1480954A1 Vanilloid receptor modulators
12/01/2004	EP1480951A1 Synthesis of indole thiazole compounds as ligands for the ah receptor
12/01/2004	EP1480950A1 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
12/01/2004	EP1480948A1 Semicarbazide derivatives and their use as antithrombotics
12/01/2004	EP1480946A2 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity
12/01/2004	EP1480941A2 Urea derivatives as hiv aspartyl protease inhibitors
12/01/2004	EP1480736A2 Microcapsules having high carotenoid content
12/01/2004	EP1480689A1 Method of treating atherosclerosis and hypercholesterolemia
12/01/2004	EP1480688A1 N-(5- 4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents
12/01/2004	EP1480687A1 Modified phosphocalcic compound, injectable composition containing same
12/01/2004	EP1480679A1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
12/01/2004	EP1480678A2 Treatment of ophthalmic disorders using urea and urea derivatives
12/01/2004	EP1480677A2 Composition for stabilizing hyaluronic acid
12/01/2004	EP1480676A1 Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents
12/01/2004	EP1480674A1 Treatment of central nervous system damage
12/01/2004	EP1480673A1 A bioadhesive agent
12/01/2004	EP1480671A2 Recombinant rsv virus expression systems and vaccines
12/01/2004	EP1480670A2 Cg3842 homologous proteins involved in the regulation of energy homeostasis
12/01/2004	EP1480667A1 Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties
12/01/2004	EP1480663A1 Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient
12/01/2004	EP1480661A1 Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics
12/01/2004	EP1480657A1 Polymers for delivering peptides and small molecules i in vivo /i
12/01/2004	EP1480656A1 Hyaluronic acid mediated adenoviral transduction
12/01/2004	EP1480655A2 Dna demethylase antisense and chemotherapy combination
12/01/2004	EP1480654A1 Carbohydrate-based anti-wrinkle and tissue remodelling compounds
12/01/2004	EP1480653A2 Ribavirin syrup formulations
12/01/2004	EP1480652A1 Use of phospholipids in peritoneal dialysis
12/01/2004	EP1480651A1 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
12/01/2004	EP1480650A1 Novel crystalline forms of the anti-cancer compound zd1839
12/01/2004	EP1480649A2 Stable pharmaceutical compositions
12/01/2004	EP1480648A1 Anti-viral compounds
12/01/2004	EP1480647A1 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
12/01/2004	EP1480646A1 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
12/01/2004	EP1480644A2 Novel heterocyclic compounds which are active as inhibitors of beta+lactamases
12/01/2004	EP1480643A1 Use of epothilones in the treatment of brain diseases associated with proliferative processes
12/01/2004	EP1480642A1 Peroxisome proliferator activated receptor modulators
12/01/2004	EP1480641A1 Substituted thiazoles and oxazoles that modulate ppar activity
12/01/2004	EP1480640A1 Peroxisome proliferator activated receptor modulators
12/01/2004	EP1480639A1 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
12/01/2004	EP1480638A2 Porphyrins with virucidal activity
12/01/2004	EP1480637A1 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
12/01/2004	EP1480636A2 Self emulsifying drug delivery systems for poorly soluble drugs
12/01/2004	EP1480634A2 Treating benign prostate hyperplasia with sarms
12/01/2004	EP1480633A2 Nematicidal fatty acid and fatty acid ester related compounds
12/01/2004	EP1480632A1 A novel dosage form of l-methionine s-sulfoximine
12/01/2004	EP1480631A2 Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators
12/01/2004	EP1480630A1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa
12/01/2004	EP1480629A1 Combination therapy for treatment of schizophrenia
12/01/2004	EP1480628A1 Use of sodium/hydrogen exchange inhibitors for the treatment of thrombotic and inflammatory diseases
12/01/2004	EP1480627A1 Methods of reducing angiogenesis

1 ... 4874 4875 4876 4877 4878 4879 4880 4881 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 ... 7860